Search

Displaying results 5591 - 5600 of 6198 in total
  1. Drug

    ATG002

    go.drugbank.com/drugs/DB05068
    Investigational

    ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors,...

  2. Drug

    Rebaudioside A

    go.drugbank.com/drugs/DB15136
    Investigational

    Rebaudioside A is under investigation in clinical trial NCT03510624 (Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus).

  3. Drug

    ONT-093

    go.drugbank.com/drugs/DB14069
    Experimental

    ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp).

  4. Drug

    Rineterkib

    go.drugbank.com/drugs/DB17560
    Investigational

    Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel

  5. Drug

    GX-19 Vaccine

    go.drugbank.com/drugs/DB15891
    Investigational

    The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea[A219758].

  6. Drug

    CCR5 mAb

    go.drugbank.com/drugs/DB05906
    Experimental

    It was generated by HGS using the Abgenix XenoMouse technology.

  7. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.

  8. Drug

    N-Methylmesoporphyrin

    go.drugbank.com/drugs/DB01911
    Experimental

    These are compounds containing a fundamental skeleton of four pyrrole nuclei united through the alpha-positions by four methine groups to form a macrocyclic structure.

  9. Drug

    Danvatirsen

    go.drugbank.com/drugs/DB14825
    Investigational

    Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).

  10. Drug

    Tovinontrine

    go.drugbank.com/drugs/DB16193
    Investigational

    Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor.